Guggenheim raised the firm’s price target on Biogen (BIIB) to $260 from $246 and keeps a Buy rating on the shares. Management expressed confidence that with successful execution of the pipeline and the Apellis (APLS) acquisition that the company “can grow well into the 2030s”, and “we agree,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Earns Buy Rating as Strong Q1 Results, Pipeline Progress and Apellis Deal Support $215 Price Target
- Biogen Earnings Call Highlights Turnaround Momentum
- Biogen price target raised to $203 from $200 at BofA
- Morning Movers: NXP Semi, Bloom Energy charged up after results
- Biogen lowers FY26 adjusted EPS view to $14.25-$15.25, consensus $15.55